Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Chicago, Illinois

This page shows live ClinicalTrials.gov search results for Chicago, Illinois, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
17846
Shown on this page
12
Current sort
Recently updated
Location scope
Chicago, IL
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Chicago, Illinois. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 1069–1080 of 17,846 matching trials in Chicago, IL.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Chicago

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Not yet recruiting Early Phase 1 Interventional

Phosphate & Kidney Stones

NCT07903961
Conditions
Kidney Stones, Calcium Oxalate Kidney Stones, Hypophosphatemia
Interventions
Neutral Phosphate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Mixed Cellularity Classic HL, Ann Arbor Stage II Nodular Sclerosis Classic HL
Interventions
Bleomycin, Brentuximab Vedotin, Dacarbazine, Doxorubicin, Nivolumab, Quality-of-Life Assessment, Vinblastine
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
16 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
Conditions
Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Interventions
Maridebart Cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
45 Years to 99 Years
Enrollment
12,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
140
States / cities
Daphne, Alabama • Fairhope, Alabama • Huntsville, Alabama + 117 more
Conditions
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
Interventions
JANX007, Darolutamide
Biological · Drug
Lead sponsor
Janux Therapeutics
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Conditions
Heart Failure, Transplant; Failure, Heart, Congenital Heart Disease
Interventions
EXCOR Active Driving System for Pediatric VAD
Device
Lead sponsor
Berlin Heart, Inc
Industry
Eligibility
Up to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 14 more
Conditions
Pain, Chronic
Interventions
Experimental: Group #1: Virtual Reality Headset, Group 2 No Virtual Reality Headset
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Nonsuicidal Self Injury, Suicidal Ideation, Depression, Anxiety
Interventions
Self-guided digital intervention for NSSI, Digital intervention for NSSI with coaching, Active control
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 24 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
HIV-1-infection
Interventions
VRC07-523LS, PGT121.414.LS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 7 more
Terminated Phase 2Phase 3 Interventional Results available

SPARK-ALL: Calaspargase Pegol in Adults With ALL

NCT04817761
Conditions
Acute Lymphoblastic Leukemia
Interventions
Calaspargase pegol (S95015)
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
22 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more
Conditions
Hidradenitis Suppurativa (HS)
Interventions
ORKA-002, Placebo
Drug · Other
Lead sponsor
Oruka Therapeutics, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
20
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 17 more
Conditions
Liver Transplant Rejection
Interventions
Erythropoietin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 74 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting No phase listed Observational

Predict Severe Traumatic Brain Injury

NCT06966713
Conditions
Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas